pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
globenewswire health·1d ago·1 min read
save

Tiziana Life Sciences CEO Ivor Elrifi boosts stake, buying 321,423 shares at $1 each

Aug 6, 2026·read at globenewswire health ↗DealPositive

Tiziana Life Sciences announced that its chief executive officer, Ivor Elrifi, purchased 321,423 common shares of the company on NASDAQ at $1.00 per share.

The purchase raises his total holding to 4,793,684 shares, indicating strong personal confidence in the company's prospects.

The company is developing intranasal foralumab, a fully human anti‑CD3 monoclonal antibody being evaluated in an expanded access program and a Phase 2a trial for non‑active secondary progressive multiple sclerosis.

source

This writeup was produced by pharmadog from original reporting by globenewswire health.

Original headline: “Tiziana Life Sciences Announces Purchase of Shares by Chief Executive Officer”

read at globenewswire health ↗
339 words · retrieved 1d ago
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
Tiziana Life Sciences Ltd10
drugs
foralumab9Lead Candidate
topics
Monoclonal Antibody12Multiple Sclerosis3

related stories

  • 1d agoTiziana Life Sciences Announces Purchase of Shares by Chief Executive Officerglobenewswire health
  • 11h agoEnsoma cuts jobs, narrows focus to lead assetBioSpace
  • 2d ago5 NextGen winners who went public this year (and which ones are hiring)BioSpace
  • Jul 29Private biotechs Caldera and Vidya raise $478M collectively in reverse go-public mergersBioSpace
  • Jul 29Earnings roundup: Biogen’s ‘resiliency,’ AstraZeneca’s growth pitch and GSK’s oncology pushBioPharma Dive